Moderna's experimental mRNA vaccine, when combined with Merck's cancer drug Keytruda, prevented cancer recurrence in a clinical trial, marking a significant milestone for personalized medicine approaches.
The combination therapy showed the ability to reduce the risk of recurrence or death in melanoma patients, according to the companies.
